Prodrug of antiviral nucleoside analog; inhibits SARS-CoV, SARS-CoV-2 and MERS-CoV infection
Molnupiravir is a broad-spectrum antiviral prodrug of the nucleoside analog β-D-N4-hydroxycytidine (NHC). Molnupiravir competes predominantly with CTP for incorporation; it induces lethal viral mutagenesis by increasing G to A and C to U transition mutations without inhibition of RNA synthesis in replicating coronaviruses, which prevents the development of viral resistance. In primary airway epithelial cell cultures, Molnupiravir dose-dependently inhibits SARS-CoV-2 infectious virus production; it also inhibits MERS-CoV and SARS-CoV with EC50 values in the submicromolar range. In mice infected with SARS-CoV or MERS-CoV, Molnupiravir improves pulmonary function, and reduces virus titer and body weight loss. Molnupiravir also displays
in vivo
efficacy against seasonal and pandemic influenza A shed virus. It is orally bioavailable.
| Marque | Tocris Bioscience |
|---|---|
| Réf. B-LABO | BL-RE-125667 |
| Réf. fabricant | 18727956 |
| Nom chimique ou matériau | β-D-N4-hydroxycytidine-5 '-isopropyl ester |
| CAS | 2492423-29-5 |
| Quantité | 50 mg |
| Cible | Antiviral Compounds |
| Formule moléculaire | C<sub>13</sub>H<sub>19</sub>N<sub>3</sub>O<sub>7</sub> |
| Pureté | 98% |
